HIMS’ Breaks into Triple-Digit Gains
Last Monday, shares of Hims & Hers Health (HIMS) rocketed more than 30% higher on the announcement of a new deal with Novo Nordisk A/S (NOV), which immediately put Novo’s blockbuster drug Wegovy on Hims’ platform. This recent surge has driven our total gain on HIMS to over 100% since I recommended it in November! Hims has been in a battle with Eli Lilly (LLY) and government regulators to maintain their ability to legally distribute GLP-1 weight loss drugs.
Read More